These studies, together with the early trial of [111In]In-ABY-025 in breast cancer patients [49], highlight the potential of SPECT/CT imaging for HER2 with Affibody-tracers, which may be a more feasible alternative to PET imaging, especially in low-income countries. Here, ERBB2 is linked to breast cancer.